title: Choroidal thickness, vascular hyperpermeability, and complement factor H in age-related macular degeneration and polypoidal choroidal vasculopathy.
abstract: OBJECTIVE
  To investigate the relationship between subfoveal choroidal thickness, choroidal vascular hyperpermeability, and complement factor H (CFH) gene polymorphism in typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV).
  
  
  METHODS
  Fifty-eight patients with typical AMD and 63 patients with PCV underwent fluorescein angiography, indocyanine green angiography (IA), and spectral-domain optical coherence tomography (OCT) using enhanced depth imaging (EDI). Subfoveal choroidal thickness was measured using EDI-OCT images, and choroidal hyperpermeability was evaluated using late-phase IA images. The major AMD-associated single-nucleotide polymorphisms were genotyped in 86 patients.
  
  
  RESULTS
  Mean subfoveal choroidal thickness was significantly lower in eyes with typical AMD than that in eyes with PCV (P = 0.025). Subfoveal choroidal thickness was greater in eyes with choroidal hyperpermeability than that in eyes without it in typical AMD (P < 0.001) and PCV (P = 0.020), and in the fellow eyes of typical AMD (P < 0.001) and PCV (P = 0.027). In eyes without choroidal hyperpermeability, the mean subfoveal choroidal thickness was greater in PCV than that in typical AMD (P = 0.001). Choroidal thickness decreased after photodynamic therapy combined with intravitreal ranibizumab in typical AMD (P = 0.016) and PCV (P = 0.036). In eyes with PCV, the I62V polymorphism in the CFH gene contributed to choroidal thickness (P = 0.043).
  
  
  CONCLUSIONS
  Choroidal thickness is related to the AMD subtypes, choroidal hyperpermeability, and I62V CFH gene polymorphism. In eyes without choroidal hyperpermeability, EDI-OCT is useful as an auxiliary measure for differentiating typical AMD and PCV.
authors.affiliation: Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
authors.forename: Pichai
authors.initials: P
authors.lastname: Jirarattanasopa
authors.forename: Sotaro
authors.initials: S
authors.lastname: Ooto
authors.forename: Isao
authors.initials: I
authors.lastname: Nakata
authors.forename: Akitaka
authors.initials: A
authors.lastname: Tsujikawa
authors.forename: Kenji
authors.initials: K
authors.lastname: Yamashiro
authors.forename: Akio
authors.initials: A
authors.lastname: Oishi
authors.forename: Nagahisa
authors.initials: N
authors.lastname: Yoshimura
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D002199:Capillary Permeability / Q000502:physiology*; D002829:Choroid / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology; D020256:Choroidal Neovascularization / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D017242:Complement Factor H / Q000235:genetics* / Q000378:metabolism; D004247:DNA / Q000235:genetics*; D005260:Female; D005451:Fluorescein Angiography; D005654:Fundus Oculi; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D006984:Hypertrophy; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D008297:Male; D009887:Ophthalmoscopy; D010778:Photochemotherapy; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D000069579:Ranibizumab; D041623:Tomography, Optical Coherence; D014792:Visual Acuity
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D017242:Complement Factor H; D004247:DNA; D000069579:Ranibizumab